FDA Brief

Warning letters Devices

FDA warning letter to

Happiest Baby, Inc.

High riskIssued Jun 15Posted Jun 15Center for Devices and Radiological Health

FDA says Happiest Baby marketed unapproved SNOO sleep sacks and hospital bundle and mishandled complaints.

What happened

FDA inspected Happiest Baby in Los Angeles from July 21 to July 25, 2025, and reviewed websites through May 7, 2026. It found the SNOO Smart Sleeper, new X-Small and X-Large sleep sacks, and SNOO Hospital Bundle marketed without required premarket authorization. It also found complaint-handling failures, including grouping many complaints into one report and missing investigation records.

What FDA found

  1. The SNOO Smart Sleeper and SNOO Hospital Bundle were marketed without an approved PMA (premarket approval) or IDE (investigational device exemption).

    section 501(f)(1)(B), 21 U.S.C. § 351(f)(1)(B); sections 515(a), 520(g)
  2. The company added X-Small and X-Large sleep sacks without submitting a 510(k) (premarket notification) for significant changes.

    section 502(o), 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k); 21 CFR 807.81(a)(3)
  3. The X-Small Sleep Sack is smaller than FDA-reviewed sizes and may be too tight, compress vital organs, limit breathing, and it is marketed for 4-8 lb infants including preterm infants.

    21 CFR 807.81(a)(3)(i) and (ii)
  4. The X-Large Sleep Sack is larger than FDA-reviewed sizes and may ride up over the mouth or neck, risking suffocation, or let an infant break free.

    21 CFR 807.81(a)(3)(i)
  5. The SNOO Hospital Bundle changes the device's intended use from home to hospital/NICU and adds a wheeled cart with new tipping and rolling risks.

    21 CFR 807.81(a)(3)(i) and (ii)
  6. The company grouped multiple complaints into one report, such as mold reports and sleep sack reports, did not adequately evaluate each complaint, and lacked records of some complaint investigations.

    21 CFR 820.198(a) and 820.198(e)

What FDA wants

FDA asks Happiest Baby to correct the unapproved-device and quality-system violations and respond within 15 working days with the steps taken and planned; it also says required premarket submissions are needed before marketing.

Who should pay attention

  • companies making infant sleep or swaddling products
  • hospitals and NICUs buying bassinets
  • suppliers and contract manufacturers for infant sleep devices

This is a summary. Read the original letter on fda.gov.

Happiest Baby, Inc.'s FDA history

Recalls in the last 12 months

Sep 23 Class II Happiest Baby, Inc
Device
Happiest Baby, Inc SNOO Sleep Sack, X-Small Model/Catalog Number: S2101-101 S2101-108-6 S2101-133 S2102-112 S2107-101 S2107-110
Extra small (ES) and Extra-large (XL) infant sleep sacks have not been reviewed for safety and effectiveness by the FDA.
Sep 23 Class II Happiest Baby, Inc
Device
Happiest Baby, Inc. SNOO Sleep Sack, X-Large Model/Catalog Number: S2101-501 S2101-508-11 S2101-508-3 S2101-508-4 S2101-508-5 S2101-508-6 S2101-508-7 S2101-512 S2101-513 S2101-532 S2101-533 S2101-534 S2101-535 S2101-536…
Extra small (ES) and Extra-large (XL) infant sleep sacks have not been reviewed for safety and effectiveness by the FDA.
Aug 12 Class II Happiest Baby, Inc
Device
Happiest Baby, Inc Pre-loved SNOO Smart Sleeper Model:S1000
This recall is retroactively being reported. Refurbished bassinets failed to meet quality standards prior to distribution.

Full company page

Similar letters to other companies

  1. AseptiKits, LLC

    AseptiKits marketed unapproved sterile-preparation device kits without FDA clearance or approval, FDA says.

    High risk
  2. Estar Technologies Ltd

    FDA warns Estar Technologies over selling seven unapproved PRP/PRF device kits in the U.S. without clearance or approval.

    High risk
  3. ProDx Health

    FDA warns ProDx Health that its HIV sample self-collection kits are sold without marketing authorization.

    High risk
  4. Genetrace

    FDA warned Genetrace that its HIV dried blood spot self-collection kit is unapproved and misbranded.

    High risk